Recent Updates
Recently added Catalysts
ICU Positive Sentiment Score: 75/100

SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference

Key Takeaway: SeaStar Medical Holding Corporation (Nasdaq: ICU) announced that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on April 18. The event will include a formal presentation followed by a question-and-answer session. SeaStar Medical specializes in developing therapies aimed at addressing hyperinflammation in critical patients, showcasing its commitment to innovation in medical technology.

Market Sentiment Analysis

POSITIVE FACTORS

  • SeaStar Medical is participating in a prominent investor conference, enhancing visibility.
  • The company is focused on innovative solutions for critically ill patients.
  • Management's presentation indicates a proactive approach in engaging with investors.

Full Press Release Details

DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time. The formal presentation will be followed by a hosted question-and-answer session.
Investors interested in viewing the live presentation can register for this event here: Virtual Healthcare Equity Conference Registration. An archived replay will be available on the Company’s website approximately 48 hours after the live event and will be archived for 90 days.
About SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
LHA Investor Relations

Tags

eaStar Medical Holding
medical device company

Frequently Asked Questions

When is SeaStar Medical presenting at the conference?

SeaStar Medical will present on April 18, 2024, at 9:30 a.m. Eastern time.

How can investors attend the live presentation?

Investors can register for the live presentation online via the event registration link.

Will there be a replay of the presentation available?

Yes, an archived replay will be available on their website approximately 48 hours later.

What type of therapies does SeaStar Medical develop?

SeaStar Medical develops cell-directed extracorporeal therapies to combat excessive inflammation.

Where can I find more information about SeaStar Medical?

More information can be found on their website or social media platforms.

Last updated: Apr 11, 2024